文献速递妇科生殖医学

甲硝唑对保留生育功能子宫内膜异位症手术后疼痛持续的影响:METROFERT随机研究

The impact of metronidazole on pain persistence after fertility-sparing endometriosis surgery: METROFERT randomized study.
PubMed 文献 · Am J Obstet Gynecol · 2024-07-15

这项随机、多中心、安慰剂对照、双盲试验将88例18至50岁接受保留生育功能子宫内膜异位症切除术的患者按1:1随机分配至口服安慰剂或甲硝唑14天组,最终72例完成随访。术后6周二元主观疼痛持续率甲硝唑组84% vs 安慰剂组88%(P=.74),无统计学显著差异,次要结局亦无显著差异。

要点

  • 保留生育功能子宫内膜异位症切除术后口服甲硝唑14天,术后6周疼痛持续率84% vs 安慰剂88%(P=.74),无统计学显著差异。
  • 生活质量、性功能及子宫内膜异位症相关疼痛评分等次要结局在两组间均未检测到显著差异。
  • 18.2%的参与者失访或中止治疗,两组间无显著差异,最终队列为72例。

核心结论

  • 保留生育功能子宫内膜异位症手术后立即给予14天口服甲硝唑方案,与安慰剂相比,在术后6周子宫内膜异位症相关疼痛症状持续方面未伴有任何显著差异。

研究设计与样本

  • 随机、多中心、安慰剂对照、双盲试验。
  • 18至50岁个体在子宫内膜异位症保留生育功能切除术后立即前瞻性随机分配至安慰剂组或口服甲硝唑14天组。
  • 2020年10月至2023年10月期间接触152例参与者,64例因不符合纳入或排除标准或拒绝参与而被排除,88例按1:1比例随机分配,18.2%失访或中止治疗且两组间无显著差异,最终队列为72例。
  • 主要结局为术后6周二元主观疼痛持续;次要结局包括依据子宫内膜异位症健康量表-5、女性性功能指数及视觉模拟量表评估的生活质量、性功能和子宫内膜异位症相关疼痛评分。

主要发现

  • 两组基线人口学特征相似。
  • 术后6周主要结局二元主观疼痛持续率甲硝唑组84% vs 安慰剂组88%(P=.74),无统计学显著改善。
  • 次要结局方面,两组治疗间未检测到显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies have shown that a disrupted microbiome is associated with endometriosis. Despite endometriosis affecting 1 in 10 reproductive-aged women, there is a lack of innovative and nonhormonal long-term effective treatments. Studies have reported an approximately 20% to 37.5% persistence of pain after fertility-sparing endometriosis surgery. Metronidazole has been shown to decrease inflammatory markers and the size of endometriosis lesions in animal studies. OBJECTIVE: To determine if modulating the microbiome with oral metronidazole for 14 days after fertility-sparing endometriosis surgery decreases pain persistence postoperatively. STUDY DESIGN: This was a randomized, multicenter, placebo-controlled, double-blind trial. Individuals 18 to 50 years old were prospectively randomized to placebo vs oral metronidazole for 14 days immediately after endometriosis fertility-sparing excision surgery. The primary outcome was binary, subjective pain persistence at 6 weeks postoperatively. Secondary outcomes included quality of life, sexual function, and endometriosis-associated pain scores according to the Endometriosis Health Profile-5, Female Sexual Function Index, and a visual analog scale. RESULTS: One hundred fifty-two participants were approached from October 2020 to October 2023 to enroll in the study. Sixty-four participants were excluded either because they did not meet inclusion or exclusion criteria or because they declined to participate. Eighty-eight participants were randomized in a 1:1 ratio to receive either the oral placebo or metronidazole after endometriosis excision surgery; 18.2% of participants were lost to follow-up or discontinued treatment and this was not significantly different between the 2 arms, yielding a final cohort of 72 participants. Baseline demographics of the 2 study groups were similar. There was no statistically significant improvement in the primary outcome of binary subjective pain persistence between the metronidazole group compared to placebo (84% vs 88%, P=.74) at 6 weeks postoperatively. Further, no significant differences between treatments were detected in the secondary outcomes. CONCLUSION: A postoperative 14-day regimen of oral metronidazole immediately after fertility-sparing endometriosis surgery was not associated with any significant differences between treatment groups in the persistence of endometriosis-related pain symptoms compared to placebo at 6 weeks.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Quevedo A, Parikh S, Reinstine J, et al. The impact of metronidazole on pain persistence after fertility-sparing endometriosis surgery: METROFERT randomized study. Am J Obstet Gynecol. 2024. PMID: 39019388. doi:10.1016/j.ajog.2024.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。